Design Therapeutics (DSGN) EV/Sales: History & Chart

Design Therapeutics, Inc.(DSGN)

Biotechnology · Carlsbad, CA

$11.97-0.45 (-3.62%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Design Therapeutics, Inc.

Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.

Carlsbad, CA

55 employees

www.designtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Pratik Shah

View full financials

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Design Therapeutics, Inc. (DSGN)	$747.61M	N/A	N/A	N/A	N/A
Apnimed, Inc. (APMD)vs ›	$742.70M	N/A	N/A	N/A	N/A
Attovia Therapeutics, Inc. (ATTO)vs ›	$753.02M	N/A	N/A	N/A	N/A
Mesa Laboratories, Inc. (MLAB)vs ›	$761.37M	3.33x	2.72x	3.17x	4.51x
Sana Biotechnology, Inc. (SANA)vs ›	$765.30M	N/A	N/A	N/A	N/A
Candel Therapeutics, Inc. (CADL)vs ›	$723.18M	N/A	777.64x	653.12x	653.12x
Achieve Life Sciences, Inc. (ACHV)vs ›	$721.69M	N/A	0.38x	0.82x	6.17x
Geron Corporation (GERN)vs ›	$776.24M	4.09x	5.53x	1615.59x	1480.74x
Lexicon Pharmaceuticals, Inc. (LXRX)vs ›	$777.34M	19.19x	12.42x	202.88x	983.65x
Varex Imaging Corporation (VREX)vs ›	$778.01M	1.22x	0.95x	1.06x	1.24x

NAME

MARKET CAP

EV/SALES RATIO

TTM

Design Therapeutics, Inc. (DSGN)

$747.61M

N/A

Apnimed, Inc. (APMD)vs ›

$742.70M

N/A

Attovia Therapeutics, Inc. (ATTO)vs ›

$753.02M